Home > Resources > Whitepapers > THE PHYSICIAN PAYMENT SUNSHINE ACT AND ESIGNATURES - ACHIEVING SUSTAINABLE COMPLIANCE

THE PHYSICIAN PAYMENT SUNSHINE ACT AND ESIGNATURES - ACHIEVING SUSTAINABLE COMPLIANCE

Applicable pharmaceutical and medical device manufacturers could face fines up to $1.15 million annually for failing to correctly report payments made to physicians, as mandated in the Transparency Reports and Reporting of Physician Ownership or Investment Interests section of the Patient Protection and Affordable Care Act, commonly referred to as the “Physician Payment Sunshine Act.” Although the Act’s writers and prominent figures within the healthcare industry have urged for swift adoption, final approval was just released February 1, 2013 – one full year after the public comment period closed. The industry has been abuzz, trying to identify best practices in aiming their processes and technologies for what is finally a confirmed, albeit ambiguous, target.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

SABIC

SABIC is a global leader in chemicals headquartered in Riyadh, Saudi Arabia. From making cars and planes more fuel-efficient, to helping conserve the world’s water supply and enabling colorful smartphone cases, we find solutions to the challenges of today to help our customers achieve their ambitions and build a better tomorrow.

OTHER WHITEPAPERS
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

Medical Afairs Transformation in Specialty Pharma

whitePaper | March 6, 2022

Pharmaceutical companies with a medical mindset and an empowered Medical Afairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates.

Read More
news image

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

Nanoform Management Presentation

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More

Medical Afairs Transformation in Specialty Pharma

whitePaper | March 6, 2022

Pharmaceutical companies with a medical mindset and an empowered Medical Afairs function are well equipped to meet the needs and expectations of patients and society. Yet, as capacity to understand and serve those needs accelerates.

Read More

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More

Nanoform Management Presentation

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics. 

Read More

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance
drug launches

Read More
More Whitepapers

Spotlight

SABIC

SABIC is a global leader in chemicals headquartered in Riyadh, Saudi Arabia. From making cars and planes more fuel-efficient, to helping conserve the world’s water supply and enabling colorful smartphone cases, we find solutions to the challenges of today to help our customers achieve their ambitions and build a better tomorrow.

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference